Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019006159) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/006159 International Application No.: PCT/US2018/040082
Publication Date: 03.01.2019 International Filing Date: 28.06.2018
IPC:
A61K 39/40 (2006.01) ,A61P 31/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
40
bacterial
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
Applicants:
SIMARD, John [CA/US]; US (US)
XBIOTECH, INC. [CA/CA]; 1055 West Hastings Street Suite 300 Vancouver, British Columbia V6E 2E9, CA
Inventors:
SIMARD, John; US
Agent:
KIM, Stanley A.; US
Priority Data:
62/527,38930.06.2017US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
(FR) COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT ET DE PRÉVENTION D'INFECTIONS PAR STAPHYLOCOCCUS AUREUS
Abstract:
(EN) Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a KD of less than 1 x 10-10 M via its Fab region paratope and is able to mediate opsinization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.
(FR) L'invention concerne des procédés et des compositions pour traiter une infection de la circulation sanguine par Staphylococcus aureus chez un sujet humain qui impliquent l'administration au sujet d'un anticorps qui se lie spécifiquement à la protéine A (SpA) de Staphylococcus aureus avec un KD inférieur à 1 x 10-10 M par l'intermédiaire de son paratope de région Fab et est capable de médier l'opsinisation de bactéries Staphylococcus aureus exprimant la SpA en présence d'au moins 1 mg/ml d'immunoglobulines IgG qui se lient à la SpA par l'intermédiaire de leurs régions Fc.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)